Answers are grounded in this paper and cite their sources.
Nanoprobes show notable luminescence and MRI contrast in Gd3TaO7 particles, suggesting new bioimaging methods.
We report the polyol-mediated synthesis of spherical Gd3TaO7 particles with controlled morphology, phase purity, and luminescence, engineered as trimodal nanoprobes for bioimaging. The method yields monodisperse particles (∼170 nm) that retain their spherical morphology even after high-temperature annealing at 800 and 1000 °C, overcoming the morphological instability and aggregation typically observed in tantalate-based systems. Structural characterization confirms the stabilization of the disordered cubic fluorite-related phase, with Eu3+ ions acting as structural and luminescent probes. The doped particles exhibit broad-band red emission and long-lived excited states, suitable for optical detection. Notably, luminescence is significantly enhanced via postsynthetic coordination with 2-thenoyltrifluoroacetone (TTA), enabling clear intracellular visualization through confocal microscopy. In parallel, undoped Gd3TaO7 particles show excellent performance as T2-weighted MRI contrast agents (r2 = 71.5 mM–1 s–1 at 7 T) and demonstrate strong X-ray attenuation for CT imaging, attributed to the presence of Gd and Ta high-Z elements. Confocal imaging confirms cellular uptake, while cytotoxicity assays in NIH-3T3 mouse fibroblasts demonstrate over 95% viability up to 1000 μg/mL, attesting to their biocompatibility. This work establishes Gd3TaO7 -based nanoprobes as robust, compositionally engineered candidates for integrated MRI, CT, and optical imaging, with enhanced luminescence achievable via TTA sensitization for advanced bioimaging applications.
No takes yet. Share an insight, caveat, or question.
Borges et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: